Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
ConclusionsIn the real-world PROSE registry, patients with moderate-to-severe AD experienced sustained improvement in disease control, symptoms, and quality of life up to 2 years after initiating dupilumab treatment. Safety data were consistent with the known safety profile of dupilumab.Trial RegistrationClinicalTrials.gov identifier: NCT 03428646.Video abstract (MP4 20,717 kb)
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
More News: Canada Health | Databases & Libraries | Dermatitis | Dermatology | Eczema | Pediatrics | Skin | Study